Universität zu Köln

Foerster, Moritz, Kuery, Patrick, Aktas, Orhan ORCID: 0000-0002-2020-9210, Warnke, Clemens, Havla, Joachim, Hohlfeld, Reinhard, Mares, Jan, Hartung, Hans-Peter ORCID: 0000-0002-0614-6989 and Kremer, David (2019). Managing Risks with Immune Therapies in Multiple Sclerosis. Drug Saf., 42 (5). S. 633 - 648. NORTHCOTE: ADIS INT LTD. ISSN 1179-1942

Full text not available from this repository.

Abstract

Since the introduction of the interferons in the 1990s, a multitude of different immunomodulatory and immunosuppressant disease-modifying therapies for multiple sclerosis (MS) have been developed. They have all shown positive effects on clinical endpoints such as relapse rate and disease progression and are a heterogeneous group of therapeutics comprising recombinant pegylated and non-pegylated interferon-beta variants, peptide combinations, monoclonal antibodies, and small molecules. However, they have relevant side effect profiles, which necessitate thorough monitoring and straightforward patient education. In individual cases, side effects can be severe and potentially life-threatening, which is why knowledge about (neurological and non-neurological) adverse drug reactions is essential for prescribing neurologists as well as general practitioners. This paper aims to provide an overview of currently available MS therapies, their modes of action and safety profiles, and the necessary therapy monitoring.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Foerster, Moritz UNSPECIFIED UNSPECIFIED UNSPECIFIED Kuery, Patrick UNSPECIFIED UNSPECIFIED UNSPECIFIED Aktas, Orhan UNSPECIFIED orcid.org/0000-0002-2020-9210 UNSPECIFIED Warnke, Clemens UNSPECIFIED UNSPECIFIED UNSPECIFIED Havla, Joachim UNSPECIFIED UNSPECIFIED UNSPECIFIED Hohlfeld, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Mares, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Hartung, Hans-Peter UNSPECIFIED orcid.org/0000-0002-0614-6989 UNSPECIFIED Kremer, David UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-149464
DOI:	10.1007/s40264-018-0782-8
Journal or Publication Title:	Drug Saf.
Volume:	42
Number:	5
Page Range:	S. 633 - 648
Date:	2019
Publisher:	ADIS INT LTD
Place of Publication:	NORTHCOTE
ISSN:	1179-1942
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; INTERFERON BETA-1A; MITOXANTRONE NOVANTRONE; DOUBLE-BLIND; ALEMTUZUMAB; NATALIZUMAB; FINGOLIMOD; OCRELIZUMAB; PLACEBO; LYMPHOPENIA Multiple languages Public, Environmental & Occupational Health; Pharmacology & Pharmacy; Toxicology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/14946